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Aims: Demonstrate superiority of insulin glargine (±glulisine) strategy versus premixed insulin strategy for
percentageof patients reachingHbA1cb7%(b53 mmol/mol)at studyendwithout anydocumentedsymptomatic
hypoglycemia (bloof glucose [BG] ≤3.1 mmol/L) in type 2 diabetes (T2DM) patients failing oral agents.
Methods: This 24-week, open-label, multinational trial randomized patients to glargine OD or premix OD or BID,
continuing metformin ± insulin secretagogue (IS). Second premix injection could be added any time; glulisine
could be added with main meal in glargine OD patients with HbA1c ≥7% and fasting blood glucose (FBG)
b7 mmol/L at week 12. IS was stopped with any second injection. Insulin titration targeted FBG ≤5.6 mmol/L.
Results:Modiﬁed intent-to-treatpopulationcomprised923patients(glargine,462;premix,461).Baselinecharacteristics
were similar (mean T2DM duration: 9 years; HbA1c: 8.7% (72 mmol/mol); FBG: 10.4 mmol/L). Primary endpoint was
achieved by 33.2% of glargine (±glulisine) and 31.4% of premix patients. Superiority was not demonstrated, but
non-inferioritywas (pre-speciﬁedmargin: 25%of premixrate).Morepatients usingpremixachieved target (52.6%
vs. 43.2%, p = 0.005); symptomatic hypoglycemia was less with glargine (1.17 vs. 2.93 events/patient–year).
Conclusions: Glargine (±glulisine) and premix strategies resulted in similar percentages of well-controlled
patients without hypoglycemia, with more patients achieving target HbA1c with premix whereas overall
symptomatic hypoglycemia was less with glargine.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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The objective of therapy for patients with type 2 diabetes (T2DM)
is to achieve andmaintain good glycemic control in order to minimize
the risk of micro- and macrovascular long-term complications
(Holman, Paul, Bethel, Matthews, & Neil, 2008; Ray et al., 2009;
Turnbull et al., 2009). While lifestyle changes and oral antidiabetic
drugs (OADs) may be sufﬁcient initially, many patients eventually
require insulin therapy (Handelsman et al., 2011; International
Diabetes Federation: IDF Clinical Guidelines Task Force, 2012;
Inzucchi et al., 2012). Basal insulin, such as the long-acting insulin
analogues insulin glargine or insulin detemir, or the intermediate-
acting neutral protamine Hagedorn (NPH) insulin, is most often
recommended as initial insulin therapy (Handelsman et al., 2011;
International Diabetes Federation: IDF Clinical Guidelines Task Force,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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also frequently used in clinical practice. Systematic reviews and
meta-analyses of glargine versus premix trials concluded that HbA1c
reduction was greater with premix, but with a higher risk of
hypoglycemia (Giugliano, Maiorino, Bellastella, Chiodini, & Esposito,
2011; Lasserson, Glasziou, Perera, Holman, & Farmer, 2009; Pontiroli,
Miele, & Morabito, 2012).
Many patients who initiate insulin therapy with basal insulin
or premix eventually need to intensify their insulin treatment
(Handelsman et al., 2011; International Diabetes Federation: IDF
Clinical Guidelines Task Force, 2012; Inzucchi et al., 2012). The
strategy for intensiﬁcation with premix entails adding another
injection, but it is not uncommon in clinical practice to start insulin
therapy with two injections of premix despite the lack of an
evidence-based algorithm for it. For basal insulin, the regimen
involves adding one injection of short-acting insulin at the main
meal of the day. The latter strategy, often described as the ‘basal plus’
strategy, is a valid choice initiating intensiﬁcation of a basal
insulin-based regimen (Davidson, Raskin, Tanenberg, Vlajnic, &
Hollander, 2011; Lankisch, Ferlinz, Leahy, & Scherbaum, 2008;
Owens, Luzio, Sert-Langeron, & Riddle, 2011). Here, we report
the results of the Insulins Glargine And gluLisine strAtegy
versus Premixed insulin strAteGy: a cOmparative Study (GALAPA-
GOS), a 24-week clinical trial designed to demonstrate the superiority
of an insulin glargine (±glulisine) strategy compared with a
premix strategy.
2. Methods
2.1. Patients
Eligible individuals were insulin-naïve men and women
with T2DM diagnosed more than 1 year ago, age 35 years or more,
with a body mass index (BMI) b40 kg/m2 and an HbA1c level of
7.0–10.5% (53–91 mmol/mol). They had to have been treated
with lifestyle interventions and oral antidiabetic agents (OADs)
for at least 3 months, with at least metformin at the maximum
tolerated dose (≥1 g/day). Exclusion criteria included type 1 diabetes,
current or anticipated pregnancy, or treatment with glucagon-like
peptide-1 (GLP-1) agonists in the 3 months prior to study entry.
Individuals with proliferative retinopathy or clinically relevant
cardiovascular, hepatic, renal, neurological, other endocrine or
major disease were also excluded. Written informed consent was
obtained from all participants, and institutional review board/
independent ethics committee approval was obtained for each
participating study center.
2.2. Study design
This was a 24-week, randomized, open-label, parallel-arm, multi-
national, phase IV study conducted at 91 sites in Europe (44), Asia (32),
and Latin America (15) between June 2010 and March 2012. The study
included a 2-week screening period, followed by 24 weeks of treatment
and 1 week of follow-up (Supplementary Fig. 1). There were ﬁve clinic
visits at weeks–2 (selection), 0 (randomization), 12, 24 (end of
treatment), and 25 (follow-up), plus telephone contact at weeks 1, 3,
4, 5, 8, 10, and 20. During the 2-week screening period, patients
continued on their existing therapy, including diet, exercise, and stable
dose of OADs. They were also trained to measure self-monitored blood
glucose (SMBG) values using a blood glucosemeter (Accu-CHEK Active,
Roche Diagnostic, Indianapolis, IN, USA), and test strips were provided
by the sponsor to record these in a log book.
At the end of the screening period, eligible patients were
randomized (1:1) to receive either glargine (once a day) or premix
(once or twice a day, based on the investigator's judgment).
Randomization was conducted using an interactive voice response/interactive Web response system. The blocked randomization
schedule was generated with alternating blocks of size 4 and 2, and
randomization was stratiﬁed on center. Patients who started with one
injection of glargine or premix continued to take their metformin,
sulfonylureas, glinides, or dipeptidylpeptidase (DPP)-4 inhibitor
therapy; any other diabetes treatments (e.g., thiazolidinediones,
alpha-glucosidase inhibitors) were discontinued at this time. Patients
who started with or later switched to two injections discontinued
their use of sulfonylureas, glinides, or DPP-4 inhibitors at that time;
metformin therapy was continued unchanged. No add-on or increase
in OADs was permitted. Premixed insulin consisted of insulin aspart
(30%) and protamine-crystallized insulin aspart (70%) in all countries
except Mexico, where it consisted of insulin lispro (25%) and insulin
lispro protamine (75%).
The dosing regimen followed the manufacturer's recommenda-
tions for insulin glargine or premix insulin. The starting dose of
glargine was 0.2 U/kg or 12 U, given in the evening. For premix,
the starting dose was 12 U at dinner if given once daily or 6 U each
at breakfast and dinner if given twice daily. Patients on insulin
glargine were to perform daily measurements of fasting blood glucose
(FBG) before breakfast, while those on premix were to measure
pre-meal BG before breakfast (and before dinner if two injections
per day) daily. A forced insulin titration was implemented every
3 days where the goal was to achieve self-monitored fasting
blood glucose (SMFBG) or pre-meal BG levels of 4.4–5.5 mmol/L
(80–100 mg/dl) (Supplementary Fig. 1). Patients used the median of
the last three SMBG values, with the exception that the lowest value
was used if it was b4.4 mmol/L. An international titration committee
reviewed SMBG values and insulin doses on an ongoing basis via a
Web site, and the study investigators were contacted by e-mail if
titration was inadequate.
Patients on premix could add another injection at any time during
the 24 weeks. As recommended in basal plus protocols, patients on
glargine for whom HbA1c remained ≥7% (≥53 mmol/mol) with FBG
b7.0 mmol/L at the end of the ﬁrst 12 weeks of treatment received in
addition one injection per day of insulin glulisine prior (0–15
minutes) to the main meal of the day. They continued with glulisine
injections until the end of the treatment period. The main meal was
the one with the highest postprandial BG (PBG) on the three 7-point
BG proﬁles performed before week 12. The starting glulisine dose was
4 U per day. Subsequent doses were titrated to achieve PBG
b7.8 mmol/L, based on the previous three PBG values measured
2 hours after the start of the main meal (Supplementary Fig. 1).
Blood samples for HbA1c were collected at screening (week –2) or
at least 4 days before the baseline visit (week 0), at least 72 hours
before week 12, and at week 24. SMBG values were recorded on three
consecutive days prior to the visit on weeks 2, 6, and 16. BG values
were also recorded whenever the patient experienced any symptoms
of hypoglycemia. Seven-point BG proﬁles were recorded on 3
consecutive days in the week prior to weeks 0, 12, and 24. Patients
self-monitored their BG values immediately before and 2 hours after
the start of breakfast, lunch, and dinner, and at bedtime, which was to
be at least 2.5 hours after dinner. The dose of insulin, plus the time
and number of injections, were recorded at each visit, including
telephone visits. Hypoglycemic episodes were recorded throughout
the study.
The primary endpoint was the proportion of patients achieving
HbA1c b7.0% (b53 mmol/mol) at study end with no documented
symptomatic hypoglycemia (conﬁrmed by a BG ≤3.1 mmol/L)
over the 24-week treatment period. Secondary endpoints
included changes in HbA1c, percentage of patients who achieved
HbA1c b7% (b53 mmol/mol) and b6.5% (b48 mmol/mol), seven-
point PG proﬁles, body weight, insulin dose, hypoglycemia, and
treatment-emergent adverse events (TEAEs). Documented sympto-
matic hypoglycemia was any event with clinical symptoms that was
considered to have resulted from hypoglycemia and conﬁrmed by a
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any event requiring the assistance of another person to administer
carbohydrate, glucagon, or other resuscitative measures. A descriptive
subgroup analysis of the number of insulin injections per treatment
arm was also performed on the primary endpoint. The study is
registered at ClinicalTrials.gov: NCT 01121835.2.3. Statistical analysis
At least 784 assessable patients were needed (392 in each arm) in
order to demonstrate that a two-sided Pearson chi-square test had
90% power to detect a treatment difference in rate at the 5%
signiﬁcance level, assuming 30% of patients reached the primary
criterion in the glargine (±glulisine) group versus 20% in the premix
group. Assuming an estimated 10% rate of non-assessable patients,
870 patients were to have been randomized (435 in each group).
All primary and secondary efﬁcacy endpoints were assessed in a
modiﬁed intent-to-treat (mITT) population, comprised of all ran-
domized subjects who received study medication and who had at
least one post-baseline assessment on-treatment of any primary or
secondary efﬁcacy variables. Additional analyses for the primary
endpoint and change in HbA1c were also performed for the per
protocol (PP) population, a subset of the mITT population that
excluded patients with a major protocol violation.
The primary objective of the study was to show superiority of the
glargine (±glulisine) strategy over a premix strategy in the
percentage of patients who achieved the primary endpoint. The
comparison between groups was performed with a Pearson
chi-square test at the 5% level; the two-sided 95% conﬁdence interval
(CI) of the difference in success rate (glargine [± glulisine] – premix)
was also calculated. The main analysis population was the mITT
population, with analysis on the PP population considered as a
supportive approach. If superiority was not demonstrated, switching
to non-inferiority was predeﬁned in the protocol objectives, with a
prospectively deﬁned non-inferiority margin of 25% of the premix
rate. This stepwise closed testing approach ensured control of the type
1 error at the level of 5% for the primary endpoint. Two-sided 95% CIs
of the difference were used. Non-inferiority was reached if the lower
limit of the CI was higher than or equal to the prespeciﬁedmargin. The
non-inferiority analysis on the mITT population had to be conﬁrmed
on the PP population. P-values provided for secondary endpoints were
not controlled for multiplicity.
The incidence and rates of hypoglycemia, bodyweight gain, insulin
dose, and occurrence of adverse events were analyzed in the safety
population, composed of all randomized and treated patients. A
Pearson chi-square or Fisher's exact test was used for categorical
variables, while an analysis of covariance was used for continuous
variables, with treatment used as the ﬁxed effect and baseline value as
a covariate. Missing data were imputed by the last observation carried
forward. The cumulative mean number of hypoglycemia events per
patient throughout the study was drawn using the Nelson–Aalen
method. The relationship between HbA1c at study end and event rate
of hypoglycemia throughout the study was analyzed using a negative
binomial regression model.
Univariate and multivariate analyses were performed to identify
potential factors that predict a successful primary outcome. Univariate
analyses were performed on a predeﬁned number of candidate
explanatory variables, with comparisons between subgroups made
by chi-square tests. The candidate explanatory variables were
gender, geographical region, age, BMI, number of antidiabetic
medications, diabetes duration, and HbA1c at baseline. Risk ratios
were calculated along with 95% CI and p-values. A stepwise logistic
regression model was used for the multivariate analysis, adjusted for
region. Odds ratios were calculated with their 95% CI and p-values
from Wald chi-square tests.3. Results
3.1. Patient disposition and characteristics
A total of 1243 patients were screened, and 934 were randomized
(1:1) to treatment with glargine or premix (Supplementary Fig. 2).
Three hundred nine patients (24.9%) failed screening, mainly due to
failure to meet the inclusion/exclusion criteria (255 [20.5%]); most
were due to out-of-range HbA1c (191 [15.4%]) or the patient not
wishing to continue (43 [3.5%]). Of the 934 randomized patients, 11
(1.2%) were randomized but not treated: 4 (0.9%) in the glargine
group and 7 (1.5%) in the premix group. A total of 923 (98.8%) patients
were randomized and treated (glargine, 462; premix, 461). There
were 860 patients who completed the 24-week study treatment: 438
(94.8%) in the glargine (±glulisine) group and 422 (91.5%) in the
premix group. More patients in the premix group (8.5%) than in the
glargine (±glulisine) group (5.2%) prematurely discontinued the
24-week study treatment (p b 0.05). For both treatment groups, the
main reason for discontinuation was the patient not wishing to
continue (1.9% for glargine [±glulisine] and 2.6% for premix). One
patient (0.1%) was randomized to the premix group but received
glargine instead. Therefore, the safety population comprised 463
patients treated with glargine (±glulisine) and 460 treated with
premix. Baseline characteristics of the randomized patients were
comparable with the total population and were balanced between the
two treatment groups (Table 1).
3.2. Insulin dose and number of insulin injections
Among the 463 patients in the safety population treated with
glargine, 197 (42.5%) also received insulin glulisine with the main
meal beginning at week 12 (Supplementary Fig. 3). Glulisine was
taken at breakfast (25.4% of patients), lunch (38.6%), or dinner
(36.0%). In the premix group, 297 (64.6%) of the 460 patients started
with one injection, while 163 (35.4%) started with two injections. Of
thosewho startedwith one injection, 129 (43.4%) switched during the
treatment period to two injections a day, for a total at the end of the
treatment period of 292 (63.5%) patients who were treated with
premix two times each day (Supplementary Fig. 3). At study end, 266
(57.5%) glargine and 168 (36.5%) premix patients remained on one
injection. As expected, more patients on glargine than on a single
premix insulin injection took concomitant sulfonylureas during the
study period (57.5% vs. 36.5%).
The mean (standard deviation [SD]) starting dose was the same
with glargine (0.17 [0.03] U/kg; 12.4 [2.1] U) and premix (0.17
[0.05] U/kg; 12.2 [2.9] U), while the overall dose at study end was 0.47
(0.33) U/kg (36.1 [24.7] U) with glargine (±glulisine) and 0.61
(0.46) U/kg (47.2 [35.8] U) for those treated with premix (Table 2).
For those who received glargine + glulisine, the mean daily dose of
glulisine starting at week 12 was 0.06 (0.02) U/kg (4.2 [1.4] U) and
increased to 0.18 (0.16) U/kg (13.6 [11.5] U) at study end, for a total
dose of 0.60 (0.38) U/kg (44.5 [28.6] U) at study end. The insulin dose
at study end for those who remained on one injection of glargine was
0.38 (0.25) U/kg (29.8 [19.2] U). For those who remained on one
premix injection, the insulin dose at study end was 0.27 (0.14) U/kg
(20.9 [11.0] U), while the dose was 0.81 (0.46) U/kg (62.3 [36.4] U) for
those taking two premix injections.
3.3. Efﬁcacy outcomes
A similar percentage of patients treated with glargine (±glulisine)
(33.2%) or premix (31.4%) achieved HbA1c b7% (b53 mmol/mol) at
study end with no documented symptomatic hypoglycemia (BG
≤3.1 mmol/L) over the 24-week treatment period (Table 2). The
glargine (±glulisine) strategy did not show superiority compared
with a premix strategy on the primary endpoint (difference in success
841P. Aschner et al. / Journal of Diabetes and Its Complications 29 (2015) 838–845rate = 1.8%; p = 0.56). Following the stepwise closed testing
approach, non-inferiority of glargine (±glulisine) was demonstrated,
as the lower limit of the 95% CI of the percentage difference was
higher than the non-inferioritymargin deﬁned prospectively as 25% of
the premix rate measure (95% CI [–4.32% to 7.91%]; non-inferiority
margin –7.85%). Non-inferiority was conﬁrmed in the PP population
(difference in success rate = 2.7%; p = 0.41). The primary endpoint
was met by 43.8% of those treated with glargine alone, 19.3% treated
with glargine + glulisine, and 37.7% and 27.9% of those treated with
once-daily and twice-daily premix, respectively.
Of the two components of the primary outcome, a greater
percentage of patients using the premix strategy achieved HbA1c
b7% (b53 mmol/mol) at study end (52.6% vs. 43.2%, p = 0.005),
whereas more patients using the glargine (±glulisine) strategy had
no documented symptomatic hypoglycemia during treatment (77.6%
vs. 63.7%, p b 0.001; Table 2). HbA1c b7% (b53 mmol/mol) was
achieved by 57.6% of those treated with glargine alone, 24.4% with
glargine + glulisine, 55.7% with once-daily and 50.9% with
twice-daily premix (Table 2). A total of 76.7% of patients treated
with glargine alone had no documented hypoglycemia during
treatment, 78.7% with glargine + glulisine, 69.8% with once-daily,
and 60.3% with twice-daily premix (Table 2).
The primary outcome was attained by 24% of patients in the
Middle and Central East, 29.0% in Latin America, 32.9% in Asia, and
36.5% in Europe. In addition to geographical region (p = 0.039), BMI
(p = 0.047), number of antidiabetic medications (p b0.001), diabetes
duration (p b 0.001), and HbA1c at baseline (p = 0.002) were
identiﬁed in univariate analyses as potential factors that predict a
successful primary outcome. In themultivariate analysis (adjusting by
geographical region), taking ≤1 antidiabetic medication at study entry
(p b 0.001), diabetes duration of b5 years (p b 0.001), HbA1c b8.2% at
baseline (p b 0.001), and living in Europe or Asia (p = 0.012) were
signiﬁcant factors that predicted success. There was also a regionTable 1
Baseline characteristics: modiﬁed intent-to-treat population.
Glargine
(n = 462)
Age, years 56.7 (9.0)
Female, n (%) 231 (50.0)
Weight, kg 75.7 (13.5)
Body mass index, kg/m2 28.4 (4.7)
Duration of diabetes, years 9.1 (6.0)
Duration of OAD treatment, years 7.9 (5.8)
Patients with ≥1 late diabetes complication, n (%) 125 (27.1)
Number of meals and snacks 4.1 (1.0)
Any prior medication (except antidiabetics), n (%) 339 (73.2)
Prior antidiabetic drugs, n (%)
Any prior OAD 461 (99.8)
Biguanides 460 (99.6)
Sulfonylureas 333 (72.1)
Glinides 35 (7.6)
GLP-1 agonist 1 (0.2)
Dipeptidylpeptidase-4 inhibitors 66 (14.3)
Alpha-glucosidase inhibitors 38 (8.2)
Thiazolidinediones 37(8.0)
Blood pressure, mmHg
Systolic 129 (14)
Diastolic 78 (8)
Cholesterol, mmol/L
Total 4.7 (1.0)
LDL 2.8 (0.9)
HDL 1.3 (0.3)
Triglycerides, mmol/L 1.9 (1.2)
HbA1c, % units 8.7 (0.9)
mmol/mol 72 (10)
Fasting blood glucose, mmol/L 8.9 (2.1)
Mean daily blood glucose, mmol/L 10.3 (2.3)
Mean (SD) or n (%).
Abbreviation: GLP, glucagon-like peptide; HDL, high-density lipoprotein; LDL, low-densityeffect (p = 0.012), but the treatment effect was homogeneous
between the regions (Supplementary Fig. 4).
Mean HbA1c values were the same at baseline in both groups
(8.7%; 72 mmol/mol), decreased throughout the study, and were
7.2 (0.9) % (55 [10] mmol/mol) with glargine (±glulisine) and 7.0
(0.9) % (53 [10] mmol/mol) with premix at study end. The least
squares (LS) mean change (standard error [SE]) from baseline to
study end was –1.48 (0.04) % and –1.64 (0.04) % with glargine
(±glulisine) and premix, respectively. The LS mean difference
between groups was 0.16% (95% CI 0.04–0.27) in favor of premix
(p = 0.008). FBG levels declined quickly in both groups, reaching a
plateau between weeks 6–12. At study end, FBG was 6.0 (1.2) mmol/l
in the glargine (±glulisine) group and 6.3 (1.4) mmol/l in the premix
group. The LS mean change (SE) from baseline was greater with
glargine (±glulisine) (–3.0 [0.06] mmol/l) than with premix (–2.6
[0.06] mmol/l), with an LS mean difference of –0.3 mmol/l (95%
CI –0.5 to –0.2; p b 0.001).
The seven-point BG proﬁle improved in both groups at study end,
with the decline in BG more pronounced for glargine (±glulisine)
before breakfast and for premix before lunch, after dinner, and at
bedtime (Fig. 1). As a consequence, the mean daily BG declined from
10.3 (2.3) mmol/L at baseline to 7.9 (1.6) mmol/L at the end of the
study with glargine (±glulisine) and from 10.5 (2.4) to 7.7 (1.4)
mmol/L with premix. The LS mean difference between the groups was
0.2 mmol/L (95% CI 0.03–0.4]; p = 0.024), in favor of premix.
3.4. Hypoglycemia and safety
Hypoglycemia by overall group as well as by the number of
injections is shown in Table 2. The incidence rate for overall
symptomatic hypoglycemia conﬁrmed by BG ≤ 3.1 mmol/L was less
with glargine (±glulisine) than premix (22.0% vs. 35.2%), as was
conﬁrmed nocturnal symptomatic hypoglycemia (7.3% vs. 18.7%). ThePremixed insulin
(n = 461)
All
(n = 923)
55.8 (9.5) 56.3 (9.2)
221 (47.9) 452 (49.0)
76.0 (13.9) 75.8 (13.7)
28.3 (4.4) 28.4 (4.5)
8.8 (5.8) 8.9 (5.9)
7.6 (5.5) 7.7 (5.7)
122 (26.5) 247 (26.8)
4.0 (1.0) 4.1 (1.0)
339 (73.7) 678 (73.5)
461 (100) 922 (99.9)
461 (100) 921 (99.8)
324 (70.3) 657 (71.2)
33 (7.2) 68 (7.4)
0 (0.0) 1 (0.1)
57 (12.4) 123 (13.3)
39 (8.5) 77 (8.3)
43(9.3) 80 (8.7)
131 (14) 130 (14)
79 (8) 78 (8)
4.7 (1.1) 4.7 (1.1)
2.8 (0.9) 2.8 (0.9)
1.2 (0.3) 1.2 (0.3)
2.0 (1.4) 2.0 (1.3)
8.7 (0.9) 8.7 (0.9)
72 (10) 72 (10)
9.0 (2.3) 8.9 (2.2)
10.5 (2.4) 10.4 (2.3)
lipoprotein; OAD, oral antidiabetic drug.
Table 2
Primary endpoint, insulin dose, and hypoglycemia — by number of injections.
Glargine ± Glulisine Premix
mITT population Overall
(N = 455)
GLA
(n = 258)
GLA + GLU
(n = 197)
Overall
(N = 446)
OD PRE
(n = 159)
BID PRE
(n = 287)
HbA1c b7% and no documented symptomatic
hypoglycemia (BG ≤3.1 mmol/L), n (%)
151 (33.2) 113 (43.8) 38 (19.3) 140 (31.4) 60 (37.7) 80 (27.9)
HbA1c b7%, n (%) 196 (43.2) 148 (57.6) 48 (24.4) 234 (52.6) 88 (55.7) 146 (50.9)
No documented symptomatic
hypoglycemia (BG ≤3.1 mmol/L), n (%)
353 (77.6) 198 (76.7) 155 (78.7) 284 (63.7) 111 (69.8) 173 (60.3)
Safety population Overall
(N = 463)
GLA
(n = 266)
GLA + GLU
(n = 197)
Overall
(n = 460)
OD PRE
(n = 168)
BID PRE
(n = 292)
Insulin dose (U/kg), mean (SD)
Starting 0.17 (0.03) 0.16 (0.03) 0.17 (0.03) 0.17 (0.05) 0.16 (0.03) 0.17 (0.05)
At study end 0.47 (0.33) 0.38 (0.25) 0.60 (0.38) 0.61 (0.46) 0.27 (0.14) 0.81 (0.46)
Symptomatic hypoglycemia (BG ≤3.1 mmol/L)
Overall symptomatic, n (%) 102 (22.0) 60 (22.6) 42 (21.3) 162 (35.2) 48 (28.6) 114 (39.0)
Events/Patient–Year 1.17 1.14 1.20 2.93 2.11 3.40
Nocturnal symptomatic, n (%) 34 (7.3) 21 (7.9) 13 (6.6) 86 (18.7) 23 (13.7) 63 (21.6)
Events/Patient–Year 0.36 0.37 0.35 1.03 1.10 1.01
Symptomatic hypoglycemia (BG ≤3.9 mmol/L)
Overall symptomatic, n (%) 211 (45.6) 118 (44.4) 93 (47.2) 251 (54.6) 74 (44.0) 177 (60.6)
Events/Patient–Year 4.51 4.17 4.85 8.37 5.52 10.03
Nocturnal symptomatic, n (%) 82 (17.7) 46 (17.3) 36 (18.3) 127 (27.6) 36 (21.4) 91 (31.2)
Events/Patient–Year 1.07 1.03 1.14 2.28 2.22 2.36
GLA, insulin glargine; GLU, insulin glulisine; PRE, premix; OD, once daily; BID, twice daily; BG, blood glucose.
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conﬁrmed by BG ≤3.1 mmol/L was less with glargine (±glulisine)
than premix (1.17 vs. 2.93), as was nocturnal hypoglycemia (0.36 vs.
1.03). The incidence and event rates were similar in those who
received only glargine or glargine + glulisine, whereas both the
incidence and event rates were greater in those receiving premix
twice daily vs. once daily. When hypoglycemia was conﬁrmed by
BG ≤3.9 mmol/L, the comparative results were similar (Table 2).
There were 9 events of severe hypoglycemia (6 patients, 1.3%) in the
glargine (±glulisine) group and 15 events (8 patients, 1.7%) in the
premixed insulin group.
The relative risk for overall and nocturnal symptomatic hypogly-
cemia was signiﬁcantly less with glargine (±glulisine) than with
premix whether hypoglycemia was conﬁrmed by BG ≤3.1 mmol/L or
by BG ≤3.9 mmol/L (Fig. 2A–D). When the estimated event rate of
overall hypoglycemia or nocturnal hypoglycemia conﬁrmed by BG
≤3.1 mmol/L was plotted against HbA1c at study end, there was a
greater risk with premix than glargine (±glulisine) treatment at all
HbA1c levels, with the difference becoming greater as good glycemicFig. 1. Seven-point BG proﬁle of overall groups at baseline and study end. Abbreviation:
ETD, end of treatment difference; EOT, end of treatment; GLA, glargine; GLU, glulisine;
PRE, premixed insulin.control was approached (Fig. 3). At an HbA1c of 7.0% and
hypoglycemia conﬁrmed by BG ≤3.1 mmol/L, the estimated event
rate of overall hypoglycemia was approximately 1.3 events/patient–
year with glargine (±glulisine) and 2.9 with premix and was
approximately 0.4 and 1.2 events/patient–year, respectively, for
nocturnal hypoglycemia. With hypoglycemia conﬁrmed by BG
≤3.9 mmol/L, the estimated event rate of overall hypoglycemia at an
HbA1c of 7.0%was approximately 4.8 events/patient–yearwith glargine
(±glulisine) and 8.7 with premix and was approximately 1.1 and 2.3
events/patient–year, respectively, for nocturnal hypoglycemia.
A similar percentage of patients treated with glargine (±glulisine)
or premix experienced at least one TEAE (34.6% vs. 35.7%). TEAEs
related to glargine or to premix were reported by 2.6% and 6.7% of
patients, respectively. Eight patients reported TEAEs related to
glulisine; TEAEs related to metformin occurred in three patients in
each group. Serious TEAEs were reported in 5.0% of the premix group
and in 2.6% of the glargine (±glulisine) group. One fatal TEAE
(pulmonary embolism) occurred in the glargine (±glulisine) group.
Mean body weight gain was similar for glargine (±glulisine) (1.1 kg)
and premix (1.4 kg; the LS mean difference was not signiﬁcant
(–0.3 kg; p = 0.12).4. Discussion
This trial was designed to compare the effects of two insulin-based
strategies in subjects with T2DM who were not achieving adequate
glycemic control with oral therapy. One strategy initiated insulin
therapy with one injection a day of the basal insulin, insulin glargine,
and added one injection of insulin glulisine, a rapid-acting insulin
before the main meal if glycemic control was insufﬁcient. This
strategy (basal-plus) is a recommended second step when basal
insulin is insufﬁcient to achieve the therapeutic goal (Handelsman
et al., 2011; International Diabetes Federation: IDF Clinical Guidelines
Task Force, 2012; Inzucchi et al., 2012). The other strategy initiated
insulin therapy with one or two injections of premixed insulin
as needed. This strategy is in line with product information for
premixed insulin use and with the way signiﬁcant numbers of
patients begin insulin therapy in routine clinical practice. The
approach of the study aimed to more accurately represent the nature
of therapy adjustment in routine clinical practice where further
Fig. 2. Cumulative rates of overall (A, B) and nocturnal (C, D) symptomatic hypoglycemia conﬁrmed with BG ≤3.1 (A, C) or BG ≤3.9 mmol/L (B, D): safety population.
Abbreviations: BG, blood glucose; GLA, glargine; GLU, glulisine; PRE, premixed insulin; RR, relative risk.
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by a protocol-driven decision tree.
The primary objective of the study was to show superiority of the
glargine (±glulisine) strategy on the composite endpoint of patients
who achieved HbA1c b7% (b53 mmol/mol) at study end and who had
no symptomatic hypoglycemia conﬁrmed by BG ≤3.1 mmol/L
throughout the treatment period. The composite endpoint was
chosen as being more clinically relevant than either hypoglycemia
or glycemic control alone, because the two are correlated. The use of
the composite endpoint was based on previous ﬁndings that glargine,
while less effective than premixed insulin in reducing HbA1c levels,
had signiﬁcantly less risk of hypoglycemia (Giugliano et al., 2011;
Lasserson et al., 2009; Pontiroli et al., 2012). Thus, it could be expected
that glargine (±glulisine) would be superior to premix using a
composite efﬁcacy/lack of hypoglycemia outcome as the primary
endpoint. However, glargine (±glulisine) did not demonstrate
superiority, though non-inferiority was demonstrated as a similar
percentage of patients from both groups achieved the endpoint.
However, titrating insulin glargine to an FBG target caused less overall
and nocturnal hypoglycemia than a similar titration scheme for
premix insulin, conﬁrming earlier ﬁndings (Giugliano et al., 2011;
Lasserson et al., 2009; Pontiroli et al., 2012).
Reasons for the failure to show superiority of glargine (±glulisine)
may be related to limitations of the study. The availability of prandial
insulin was different in the two groups. Patients in the premixed
insulin group were given prandial insulin from the beginning and
could add another injection at any time during the study, whereas
those on glargine could only add one prandial insulin injection
starting at week 12 as recommended in basal plus protocols. Thus,
prandial insulin could be given twice daily with premixed insulin,
compared with only once daily with glargine (±glulisine), and itcould be given for the entire study duration in those who were
initiated on a twice-daily dose, or at least for longer than in the
glargine + glulisine group when the second premix injection was
initiated prior to week 12. This disparity in dosing regimen led to a
disparity in insulin dose, with patients on glargine (±glulisine)
receiving less insulin over the course of the study, particularly when
both groups received two injections. While limiting the use of rapid
insulin in the glargine group to the second three months of the study
was a limitation, this strategy assured an efﬁcient titration of the basal
insulin. Another possible limitation was the greater use of insulin
secretagogues in patients on glargine than in patients on premix
who received two injections. This may have contributed to the
good response in the glargine-only group, even though the
insulin dose was less. The withdrawal of insulin secretagogues
when glulisine was added may have contributed to the relative
ineffectiveness of the basal insulin strategy due to the absence of
a prandial treatment at the other meals. Also, it is clear that
postprandial and pre-meal glucose levels during the day contributed
to overall glycemia with both regimens.
In a study with a similar composite endpoint, patients with poor
glycemic control on metformin and sulfonylurea were randomized to
add glargine or to stop OADs and to start premixed insulin twice daily
(Malone, Kerr, Campaigne, Sachson, & Holcombe, 2004). Both
regimens were strictly titrated to a fasting or preprandial blood
glucose ≤5.6 mmol/L, and glarginewas found to be superior to premix
in achieving HbA1c b7% (b53 mmol/mol) without conﬁrmed noctur-
nal hypoglycemia. Other studies have compared basal insulin and
premixed insulin, albeit without a similar composite endpoint. In a
24-week study with a patient population similar to GALAPAGOS,
treatment with glargine + glimepiride and metformin resulted in
greater HbA1c reduction and less conﬁrmed hypoglycemia than
Fig. 3. Estimated rates of symptomatic hypoglycemia versus HbA1c at study end: overall (A, B) and nocturnal (C, D) symptomatic hypoglycemia conﬁrmed by BG ≤3.1 mmol/L (A, C)
or BG ≤3.9 mmol/L (B, D). Abbreviations: BG, blood glucose; GLA, glargine; PRE, premixed insulin.
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(Janka et al., 2005). More patients on glargine achieved targeted goals
for HbA1c and FPG, while body weight gain was not signiﬁcantly
different between treatments. In the 4-T study (Holman et al., 2007),
patients who were uncontrolled on maximum doses of metformin
and sulfonylurea added either short-acting (three times a day),
premix (twice a day), or basal insulin (insulin detemir, once or twice a
day). By 24 weeks, premixed insulin and prandial insulin were
slightly more efﬁcacious than basal insulin but with greater risks of
hypoglycemia, as in the current study, and weight gain.
The strategy of adding a rapid-acting insulin dose to basal insulin
(“basal plus”) was examined in a 6-month proof-of-concept study
where patients who were on glargine for 3 months and who had
HbA1c N7% (N53 mmol/mol) were randomized to either continue
their prior OAD and glargine therapy or to add a single dose of
glulisine immediately prior to the main meal for a further 3 months.
More participants on glargine (+glulisine) reached HbA1c b7.0%
(b53 mmol/mol) than on glargine only, with signiﬁcantly greater
reduction of HbA1c, while rates of hypoglycemia and mean weight
changewere comparable between the treatment groups (Owens et al.,
2011). A more recent study randomized subjects with T2DM and
HbA1c N7% to twice-daily premixed insulin, once-daily insulin
glargine plus zero to one prandial insulin glulisine injection, or
insulin glargine plus zero to three prandial injections (Riddle,
Rosenstock, Vlajnic, & Gao, 2014). During the ﬁrst 24 weeks of the
trial, their results were quite similar to ours —mean HbA1c reduction
was the same with premix and basal plus one prandial bolus, but the
hypoglycemia rate was higher with premix. HbA1c did not improve
during the following six months. In our study, adding an injection ofprandial insulin to the basal insulin did not improve the glycemic
control, even after reaching a sizeable dose.
In conclusion, our results show that a glargine- or premixed
insulin-based regimen resulted in similar percentages of well-
controlled patients without hypoglycemia, demonstrating non-
inferiority, but not superiority, of glargine (±glulisine). More patients
achieved HbA1c b7% (b53 mmol/mol) with premixed insulin, whereas
overall symptomatic hypoglycemia was less with glargine. Hypoglyce-
mia should be considered in evaluating the treatment beneﬁt/risk.
Author contributions
P.A., B.S., F.G.-P., and A.C. contributed to the study design, data
analysis, writing the manuscript, and critically re-reading the
manuscript. W.L. contributed to the study design, study conduct/
data collection, data analysis, writing the manuscript, and critically
re-reading the manuscript. V.L. contributed to the study conduct/data
collection, data analysis, and critically re-reading the manuscript.
M.-P.D. contributed to the study design, data analysis, and critically
re-reading the manuscript. V.P. contributed to the study conduct/data
collection, data analysis, writing the manuscript, and critically
re-reading the manuscript. All authors had free access to the data.
Acknowledgments
This studywas funded by Sanoﬁ. Editorial support was provided by
Tom Claus, PhD, of PPSI (a PAREXEL company) and was funded
by Sanoﬁ.
845P. Aschner et al. / Journal of Diabetes and Its Complications 29 (2015) 838–845Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jdiacomp.2015.04.003.
References
Davidson, M. B., Raskin, P., Tanenberg, R. J., Vlajnic, A., & Hollander, P. (2011). A
stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and
basal insulin treatment failure. Endocrine Practice, 17(3), 395–403.
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2011). Treatment
regimens with insulin analogues and haemoglobin A1c target of b7% in type 2
diabetes: A systematic review. Diabetes Research and Clinical Practice, 92(1), 1–10.
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G.
A., et al. (2011). American Association of Clinical Endocrinologists Medical
Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive
care plan. Endocrine Practice, 17(Suppl. 2), 1–53.
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. (2008). 10-year
follow-up of intensive glucose control in type 2 diabetes. The New England Journal of
Medicine, 359(15), 1577–1589.
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., et al. (2007).
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. The
New England Journal of Medicine, 357(17), 1716–1730.
International Diabetes Federation: IDF Clinical Guidelines Task Force (2012). Global
guideline for type 2 diabetes. International Diabetes Federation Web site [Retrieved
May 15, 2014 from https://www.aace.com/ﬁles/dm-guidelines-ccp.pdf].
Inzucchi, S. E., Bergenstal, R.M.,Buse, J. B., Diamant,M., Ferrannini, E., Nauck,M., et al. (2012).
Management of hyperglycemia in type 2 diabetes: a patient-centered approach:
Position Statement of the American Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD). Diabetes Care, 35(6), 1364–1379.
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Jarvinen, H.
(2005). Comparison of basal insulin added to oral agents versus twice-dailypremixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care,
28(2), 254–259.
Lankisch, M. R., Ferlinz, K. C., Leahy, J. L., & Scherbaum, W. A. (2008). Introducing a
simpliﬁed approach to insulin therapy in type 2 diabetes: A comparison of two
single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic
drugs. Diabetes, Obesity & Metabolism, 10(12), 1178–1185.
Lasserson, D. S., Glasziou, P., Perera, R., Holman, R. R., & Farmer, A. J. (2009). Optimal
insulin regimens in type 2 diabetes mellitus: Systematic review andmeta-analyses.
Diabetologia, 52(10), 1990–2000.
Malone, J. K., Kerr, L. F., Campaigne, B. N., Sachson, R. A., & Holcombe, J. H. (2004).
Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine
plus metformin: A 16-week, randomized, open-label, crossover study in patients
with type 2 diabetes beginning insulin therapy. Clinical Therapeutics, 26(12),
2034–2044.
Owens, D. R., Luzio, S. D., Sert-Langeron, C., & Riddle, M. C. (2011). Effects of initiation
and titration of a single pre-prandial dose of insulin glulisine while continuing
titrated insulin glargine in type 2 diabetes: A 6-month 'proof-of-concept' study.
Diabetes, Obesity & Metabolism, 13(11), 1020–1027.
Pontiroli, A. E., Miele, L., & Morabito, A. (2012). Metabolic control and risk of
hypoglycaemia during the ﬁrst year of intensive insulin treatment in type 2
diabetes: Systematic review and meta-analysis. Diabetes, Obesity & Metabolism,
14(5), 433–446.
Ray, K. K., Seshasai, S. R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., et al.
(2009). Effect of intensive control of glucose on cardiovascular outcomes and death
in patients with diabetes mellitus: A meta-analysis of randomised controlled trials.
Lancet, 373(9677), 1765–1772.
Riddle, M. C., Rosenstock, J., Vlajnic, A., & Gao, L. (2014). Randomized, 1-year
comparison of three ways to initiate and advance insulin for type 2 diabetes:
Twice-daily premixed insulin versus basal insulin with either basal-plus one
prandial insulin or basal-bolus up to three prandial injections. Diabetes, Obesity &
Metabolism, 16(5), 396–402.
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W.
C., et al. (2009). Intensive glucose control and macrovascular outcomes in type 2
diabetes. Diabetologia, 52(11), 2288–2298.
